Sphingomyelin phosphodiesterase 2

BE0012101ProteinHumansSMPD2

Catalyzes, at least in vitro, the hydrolysis of sphingomyelin to form ceramide and phosphocholine (PubMed:10608884). It is acted on by 1 drug in DrugBank.

Gene name
SMPD2
UniProtKB entry
O60906Swiss-Prot
Cellular location
Cell membrane
Residues / weight
423 residues · 47,645 Da
Also known as
3.1.4.12 · Lyso-PAF-PLC · Lyso-platelet-activating factor-phospholipase C · N-SMase · Neutral sphingomyelinase

Resolves to

Protein
UniProtO60906UniProt nameNSMA_HUMAN
Gene
HGNCHGNC:11121NCBI Gene6610GeneCardsSMPD2
Pharmacology
KEGGhsa:6610
Structure
PDB8J2F
Drugs

What you can answer from here — as of September 03, 2024

1DrugApproved to experimental, with action, bond type and pharmacological action
Sign in
2GO termsFunction, process and component, as structured annotations
Sign in
1Pfam domainDomain architecture mapped to Pfam families and clans
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which approved drugs act on Sphingomyelin phosphodiesterase 2, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In